Clinical Trials on Disorder Related to Bone Marrow Transplantation in Japan

Total 113 results

Pfizer

Active, not recruiting

ATGAM General Investigation

Aplastic Anemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of AMG531(Romiplostim) in Patients With Aplastic Anemia

Aplastic Anemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia

Aplastic Anemia

Japan
Astellas Pharma Inc

Completed

A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Kyowa Kirin Co., Ltd.

Enrolling by invitation

Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia

Aplastic Anemia

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Nagoya University

Unknown

Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA

Acquired Aplastic Anemia.

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia

Aplastic Anemia

Japan, Korea, Republic of
Pfizer

Completed

A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia

Aplastic Anemia

Japan
Novartis Pharmaceuticals

Completed

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Aplastic Anemia

Japan
Perseus Proteomics Inc.

Recruiting

Safety Evaluation Study for Patients With Polycythemia Vera

Polycythemia Vera

Japan
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
PharmaEssentia Japan K.K.

Recruiting

A Study to Evaluate P1101 in Japanese PV Patients

Polycythemia Vera (PV)

Japan
Kyushu University
Novartis; Kurume University; Fukuoka University; University of Occupational and... and other collaborators

Unknown

Ranibizumab Treatment for Age-Related Macular Degeneretion (QUATRO)

Visual Disorder Due to Age-related Macula Degeneration

Japan
Novartis Pharmaceuticals

Active, not recruiting

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (REACTS)

Severe Aplastic Anemia (SAA)

Japan, Korea, Republic of, China, Taiwan
PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
PharmaEssentia Japan K.K.

Completed

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Polycythemia Vera (PV)

Japan
Andreas Benesic, MD
MetaHeps GmbH

Unknown

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Adverse Reaction to Drug | Drug-induced Disorder of Liver

Hong Kong, Australia, Germany, Japan, Korea, Republic of
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Novo Nordisk A/S

Completed

A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Achondroplasia | Genetic Disorder

Japan
Kanto CML Study Group
Epidemiological and Clinical Research Information Network

Completed

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib (CMR-CML)

Chronic Myeloid Leukemia

Japan
Kanto CML Study Group
Epidemiological and Clinical Research Information Network

Completed

A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Japan
Novo Nordisk A/S

Completed

Special Survey for Long Term Application

Achondroplasia | Genetic Disorder

Japan
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
Kanto CML Study Group

Unknown

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan (D-First)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Myelogenous Leukemia, Chronic, Chronic Phase

Japan
Shimousa Hematology Study Group
Epidemiological and Clinical Research Information Network

Unknown

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Chronic Myeloid Leukemia

Japan
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Kanto CML Study Group

Unknown

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Myelogenous Leukemia, Chronic, Chronic Phase

Japan
Pfizer

Completed

Safety And Efficacy Of Bosutinib (BLF)

Chronic Myelogenous Leukemia

Japan
Novo Nordisk A/S

Completed

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Novo Nordisk A/S

Completed

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Novo Nordisk A/S

Completed

Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome (NordiPAD)

Turner Syndrome | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Genetic Disorder

Japan
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
Versartis Inc.

Terminated

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Growth Disorders | Pediatric Growth Hormone Deficiency

Japan
Novartis Pharmaceuticals

Completed

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Primary Myelofibrosis (MF)

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Keio University

Completed

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

Japan
Celgene

Completed

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Myelodysplastic Syndromes | Multiple Myeloma

Japan
Incyte Corporation

Recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (LIMBER)

Anemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, France, Italy, Japan, United Kingdom, Canada
Kyowa Kirin Co., Ltd.

Completed

Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease (MBD-5D)

End Stage Renal Disease | Hyperparathyroidism, Secondary

Japan
Novartis Pharmaceuticals

Completed

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Primary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MF

Taiwan, Japan, Korea, Republic of, China
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
AbbVie

Active, not recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Spain, Sweden, Turkey, Korea, Republic of
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy

Clinical Trials on Disorder Related to Bone Marrow Transplantation in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations